Description
Faslodex offers a breakthrough in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. With its active ingredient Fulvestrant, Faslodex provides a powerful therapy option that targets and blocks estrogen receptors, ultimately inhibiting tumor growth.
Manufactured with precision by Astrazeneca Pharma India Ltd., Faslodex comes in a convenient injectable form, ensuring swift and effective administration under medical supervision.
Key Features:
- Potent Anti-Estrogen Action: Faslodex contains Fulvestrant, a selective estrogen receptor degrader (SERD), which works by binding to estrogen receptors and blocking the effects of estrogen in cancer cells.
- Effective Metastatic Breast Cancer Treatment: Faslodex is specifically designed to combat hormone receptor-positive metastatic breast cancer in postmenopausal women, offering hope and improved outcomes.
- Clinically Proven Efficacy: Backed by extensive clinical trials, Faslodex has demonstrated significant efficacy in delaying disease progression and improving overall survival rates.
- Convenient Administration: With its injectable form, Faslodex ensures convenient and precise dosing, allowing for seamless integration into treatment regimens.
- Trusted Manufacturer: Manufactured by Astrazeneca Pharma India Ltd., a renowned pharmaceutical company known for its commitment to quality and patient care, Faslodex ensures reliability and safety.
For patients battling metastatic breast cancer, Faslodex stands as a beacon of hope, offering a promising therapeutic option to combat the disease and improve quality of life.
**Important Note: Faslodex (Fulvestrant 250 mg Injection) should only be administered under the guidance and supervision of a qualified healthcare professional. Dosage and treatment regimen should be determined based on individual patient factors and medical history.
Reviews
There are no reviews yet.